Monoclonal antibody against a peptide specified by [Met]-enkephalin complementary RNA recognizes the delta-class opioid receptor

Immunol Lett. 1989 Feb;20(3):181-6. doi: 10.1016/0165-2478(89)90077-1.

Abstract

Monoclonal antibodies (MAB) were developed which recognize a peptide, His-Glu-Ala-Pro-Ile (HEAPI), encoded by the RNA complementary to the mRNA specifying [Met]-enkephalin. One such MAB (designated 6193) exhibited a high degree of reactivity to the peptide sequence. Other characteristics of 6193 MAB include: the ability to block opioid ligand binding in a radioreceptor assay; agonist activity similar to opioid peptides in suppressing cAMP production; and the recognition of a 58 kDa protein on the surface of the neuroblastoma x glioma cell line, NG108-15. These results are consistent with a reactivity of 6193 MAB with the delta-class opioid receptor.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / biosynthesis*
  • Antibodies, Monoclonal / immunology
  • Cell Line
  • Cell Separation
  • Cells, Cultured
  • Cyclic AMP / metabolism
  • Enkephalin, Methionine / immunology*
  • Flow Cytometry
  • Mice
  • Mice, Inbred BALB C
  • Oligopeptides / immunology
  • RNA
  • RNA, Complementary
  • Receptors, Opioid / metabolism*

Substances

  • Antibodies, Monoclonal
  • Oligopeptides
  • RNA, Complementary
  • Receptors, Opioid
  • Enkephalin, Methionine
  • RNA
  • Cyclic AMP